An Extension of Deep Pathway Analysis: A Pathway Route Analysis Framework Incorporating Multi-dimensional Cancer Genomics Data

  title={An Extension of Deep Pathway Analysis: A Pathway Route Analysis Framework Incorporating Multi-dimensional Cancer Genomics Data},
  author={Yue Zhao},
  • Yue Zhao
  • Published in ISBRA 10 October 2017
  • Biology
Recent breakthroughs in cancer research have come via the up-and-coming field of pathway analysis. By applying statistical methods to prior known gene and protein regulatory information, pathway analysis provides a meaningful way to interpret genomic data. While many gene/protein regulatory relationships have been studied, never before has such a significant amount data been made available in organized forms of gene/protein regulatory networks and pathways. However, pathway analysis research is… 
Recurrent Neural Network for Gene Regulation Network Construction on Time Series Expression Data
A new way of exploring potential transcription factor targets in which the Recurrent Neural Network is used to model time series gene expression data, which shows that the RNN method can identify transcription Factor targets with higher accuracies than most of existing approaches.


Deep pathway analysis incorporating mutation information and gene expression data
We propose a new way of analyzing biological pathways in which the analysis combines both transcriptome data and mutation information and uses the outcome to identify routes of aberrant pathways
Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM
PARADIGM identified consistent pathway-level activities for subsets of the GBM patients that are overlooked when genes are considered in isolation, suggesting that therapeutics might be chosen that target genes at critical points in the commonly perturbed pathway(s) of a group of patients.
Pathway Relevance Ranking for Tumor Samples through Network-Based Data Integration
A new pathway relevance ranking method that is able to prioritize pathways according to the information contained in any combination of tumor related omics datasets is presented, demonstrating the method’s ability to correctly identify key pathways, irrespective of tumor subtype.
A novel signaling pathway impact analysis
A novel signaling pathway impact analysis (SPIA) that combines the evidence obtained from the classical enrichment analysis with a novel type of evidence, which measures the actual perturbation on a given pathway under a given condition.
Bayesian Pathway Analysis of Cancer Microarray Data
The improved BPA system was applied on real cancer microarray data sets in order to investigate the pathways that are commonly active in different cancer types and achieved over 98% accuracy in identifying the active pathways.
Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
It is demonstrated how the GSEA method yields insights into several cancer-related data sets, including leukemia and lung cancer, where single-gene analysis finds little similarity between two independent studies of patient survival in lung cancer.
In Response to Comment on "Network-constrained regularization and variable selection for analysis of genomic data"
A network-constrained regularization procedure that efficiently utilizes the known pathway structures in identifying the relevant genes and the subnetworks that might be related to phenotype in a general regression framework is introduced.
Algorithms for Detecting Significantly Mutated Pathways in Cancer
This work uses a diffusion process on the interaction network to define a local neighborhood of "influence" for each mutated gene in the network, and derives a two-stage multiple hypothesis test to bound the false discovery rate (FDR) associated with the identified subnetworks.
Genomics of the NF-κB signaling pathway: hypothesized role in ovarian cancer
Evidence suggests that NF-κB plays a critical role in ovarian cancer, yet inherited variation in these genes has not been thoroughly assessed in relation to disease risk or outcome, so a collection of variants in key genes is presented and creation of a custom genotyping array is suggested.